Company Description
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
The company distributes its products through independent distributors and directly under the ESAB and DJO brands.
Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1995 |
| IPO Date | May 8, 2008 |
| Industry | Specialty Industrial Machinery |
| Sector | Industrials |
| Employees | 6,550 |
| CEO | Matthew L. Trerotola |
Contact Details
Address: 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States | |
| Phone | (302) 252-9160 |
| Website | enovis.com |
Stock Details
| Ticker Symbol | ENOV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420800 |
| CUSIP Number | 194014502 |
| ISIN Number | US1940145022 |
| Employer ID | 54-1887631 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Matthew L. Trerotola | Chief Executive Officer and Chairman |
| Phillip Benjamin Berry | Senior Vice President and Chief Financial Officer |
| Patricia A. Lang | Senior Vice President and Chief Human Resources Officer |
| Daniel A. Pryor | Executive Vice President of Strategy and Business Development |
| Brady R. Shirley | Executive Advisor and Director |
| John Kleckner | Vice President, Controller and Chief Accounting Officer |
| Derek Leckow | Vice President of Investor Relations |
| Bradley J. Tandy | Senior Vice President and Chief Legal Officer |
| Katie Sweet | Vice President of Corporate Communication |
| Terry Ross | Group President Prevention and Recovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 25, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 22, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 8-K/A | [Amend] Current report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |